BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June

Day

• 2
• 3
• 4
• 5
• 6
• 7
• 10
• 11
• 12
• 13
• 14
• 17
• 18
• 19
• 20
• 21
• 24
• 25
• 26
• 27
• 28
• 31

• 

  Business

  “Perfect Patient” Industry Burdens; Exits and Investment in Women’s Health

  In this episode of Denatured, BioSpace’s Head of Insights Lori Ellis and Miruna Sasu, CEO of COTA, discuss the challenges of inclusion and exclusion criteria of clinical trial patients, and reflect on current investment approaches around women’s health.

  March 13, 2025

   · 

  1 min read

   · 

  Lori Ellis
• 

  Mergers & acquisitions

  Acelyrin Adopts Poison Pill to Ward Off Tang Capital Buy

  The move by Acelyrin’s board comes as the venture capital firm has taken larger and larger stakes in the company in an attempt to disrupt a merger with Alumis.

  March 13, 2025

   · 

  1 min read

   · 

  Dan Samorodnitsky
• 

  Vaccines

  Trump Administration Pulls CDC Nominee Dave Weldon at Last Minute

  As Marty Makary and Jay Bhattacharya sail through the Senate health committee vote, Weldon’s confirmation hearing is canceled. Guggenheim Partners heralded the last-minute move to revoke Dave Weldon’s nomination as “a positive sign for reigning in vaccine criticism.”

  March 13, 2025

   · 

  1 min read

   · 

  Annalee Armstrong
• 

  Business

  Houston’s Life Sciences Scene Continues Boosting Its Reputation

  While Houston isn’t yet on the same level as major life sciences hubs, it has plenty to offer and room to grow, according to CNS Pharmaceuticals, RadioMedix and Greater Houston Partnership executives.

  March 13, 2025

   · 

  6 min read

   · 

  Angela Gabriel
• 

  Mergers & acquisitions

  Troubled Drugmakers Mallinckrodt, Endo Officially Announce $6.7B Merger

  Both Mallinckrodt and Endo have previously declared bankruptcy, linked to opioid-related lawsuits.

  March 13, 2025

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Manufacturing

  J&J, Legend Pump $150M Into Manufacturing in Bid to Double Carvykti Production

  Johnson & Johnson and Legend Biotech hope to hit blockbuster status for Carvykti this year.

  March 13, 2025

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Autoimmune disease

  Amgen’s Uplizna Deepens Response Against Myasthenia Gravis at 1 Year

  With what analysts are calling “strong” data, Amgen plans to file a regulatory submission for Uplizna, currently approved for a rare ocular autoimmune disorder, in myasthenia gravis, in the first half of 2025.

  March 13, 2025

   · 

  1 min read

   · 

  Tristan Manalac
• Press Releases

  Annual General Meeting 2025 – GN Store Nord A/S

  March 13, 2025

   · 

  3 min read
• Press Releases

  Clene Demonstrates Strengthened ALS Survival Benefit with CNM-Au8® Treatment

  March 13, 2025

   · 

  9 min read
• Press Releases

  Epilepsia Publishes Final Analysis of Open-Label Extension Study of Long-Term Safety and Effectiveness of FINTEPLA® (fenfluramine) in Children and Adults with Dravet Syndrome

  March 13, 2025

   · 

  20 min read